Why use Markov simulation models for estimating the effect of cancer screening policies when randomised controlled trials provide better evidence?

Abstract

Get full access to this article

View all access options for this article.

References

Uhry

Hédelin

Colonna

. Multi-state Markov models in cancer screening evaluation: a brief review and case study. Stat Methods Med Res 2010; 19: 463–486.

Lin

Lipsitz

Miller

Janakiraman

. U.S. Preventive Services Task Force Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 192–199.

Baum

Thornton

Gøtzsche

. Breast cancer awareness month. Still awaiting screening facts. BMJ 2010; 341: c6152–c6152.

Institut National du Cancer. ‘Dynamique d’évolution des taux de mortalité des principaux cancers en France’, http://www.e-cancer.fr/component/docman/doc_download/5986-dynamique-devolution-des-taux-de-mortalite-des-principaux-cancers-en-france-novembre-2010 (accessed December 2010).

Jørgensen

Zahl

Gøtzsche

. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ 2010; 340: c1241–c1241.